Moderna’s Studies

21% of those in the High Dose Group, and 6% of those in the low dose group in Moderna’s preliminary Covid Vaccine trials experienced Grade 3 adverse events (Severe/Medically significant Adverse Event)

After the first vaccine dose, 33% in the low dose group, 67% in the medium dose group, and 53% in the high dose group experienced mild or moderate systemic adverse events.

After the second dose, 54% in low dose group, 100% in medium dose group, and 100% in the High dose experienced systemic adverse events, with 21% reporting one or more severe events”